From: TROP2 methylation and expression in tamoxifen-resistant breast cancer
ERpos primary to ERneg (n = 6) | ERpos primary to ERpos (n = 12) | |||
---|---|---|---|---|
Patients | ||||
Age (in years) mean (SD), range | ||||
At primary | 53 (8.1), 42–65 | 58 (15.8), 37–84 | ||
At recurrence | 60 (6.1), 53–68 | 65 (15.6), 40–90 | ||
Menopausal n (%) | ||||
At primary | 2 (33%) | 6 (50%) | ||
At recurrence | 3 (50%) | 8 (66.6%) | ||
TTR (in months) mean (SD), range | 82.8 (77.6) 17–216 | 84.1 (72.5), 12–252 |
ERpos primary (n = 6) | ERneg recurrent (n = 6) | ERpos primary (n = 12) | ERpos recurrent (n = 12) | |
---|---|---|---|---|
Tumors | ||||
PR status n (%) | ||||
+ | 3 (50) | 0 | 11 (91.6) | 9 (75) |
− | 3 (50) | 6 (100) | 1 (8.3) | 3 (25) |
HER2 status n (%) | ||||
+ | 2 (33.3) | 3 (50) | 1 (8.3) | 2 (16.6) |
− | 4 (66.6) | 3 (50) | 11 (91.6) | 10 (83.4) |
Ki67 IHC n (%) | ||||
Low (≤ 15) | 6 (100) | 4 (66.6) | 9 (75) | 8 (66.6) |
High (> 15) | 0 | 2 (33.3) | 3 (25) | 4 (33.4) |
Tumor grade n (%)a | ||||
0 | 2 (33.3) | 2 (33.3) | 1 (9.1) | 2 (16.7) |
1 | 0 | 0 | 3 (27.3) | 2 (16.7) |
2 | 3 (50) | 0 | 4 (36.3) | 3 (25) |
3 | 1 (16.6) | 4 (66.6) | 3 (27.3) | 5 (41.6) |
Tumor type n (%) | ||||
DCIS | 2 (33.3) | 2 (33.3) | 1 (8.3) | 2 (16.7) |
IDC | 3 (50) | 4 (66.6) | 8 (66.7) | 6 (50) |
ILC | 0 | 0 | 2 (16.7) | 3 (25) |
IDLC | 1 (16.6) | 0 | 1 (8.3) | 1 (8.3) |